Leishmaniasis is a parasitic disease that affects humans and animals (like dogs). It is caused by the protozoon Leishmania infantum, or L. infantum and transmitted from one host to another through the bite of an infected phlebotomine sand fly vector. According to reports, over 20 species of Leishmania can cause various forms of leishmaniasis, including cutaneous, mucocutaneous, and visceral forms.
Some vaccines such as CaniLeish, Leish-Tec, and Letifend have shown remarkable success in the prevention of canine leishmaniasis. They have been proven to provide protection for dogs, preventing zoonotic transmission of leishmaniasis to humans, and have obtained veterinary permission for use.
Leishmune (Fort Dodge Animal Health)
Leishmune is the first approved canine visceral leishmaniosis vaccine, which was sold in Brazil from 2004 to 2014 (withdrawn in 2014). It is composed of a purified fucose mannose ligand (FML) isolated from Leishmania donovani and a saponin adjuvant. Leishmune vaccine is manufactured by the Fort Dodge Animal Health (now part of Pfizer).
CaniLeish (Virbac)
CaniLeish, another fractionated vaccination created by Virbac to prevent canine leishmaniasis, has been sold in Europe since 2011. CaniLeish is made up of a highly purified saponin fraction known as QA-21 adjuvant and purified secreted proteins (ESP) of L. infantum (LiESP).
Leish-Tec (Hertape)
Leish-Tec is a recombinant subunit vaccine. It comprises recombinant protein A2 that is obtained from L. donovani amastigotes as antigen, and saponin as vaccine adjuvant. Leish-Tec is available for sale in Brazil and produced by Hertape Calier Saude Animal (acquired by Ceva).
LetiFend (Laboratorios Salud Animal)
Laboratorios Salud Animal (LETI Pharma) created LetiFend, which has been licensed in Europe since February 2016. LetiFend is a recombinant subunit vaccine composed of a chimerical protein (protein Q) consisting of five antigenic fragments of four different L. infantum proteins (ribosomal proteins LiP2a, LiP2b and LiP0 and the histone H2A). Engineered Escherichia coli (E. coli) expresses the recombinant chimeric protein Q. To LetiFend, no adjuvant is applied.
Yaohai Bio-Pharma Offers One-Stop CDMO Solution for Leishmania Vaccines
EN
AR
HR
CS
DA
NL
FI
FR
DE
EL
IT
JA
KO
NO
PL
PT
RO
RU
ES
SV
IW
ID
LV
LT
SR
SK
SL
UK
VI
ET
HU
TH
TR
FA
AF
MS
BE
MK
UR
BN
